A phase III study to evaluate the efficacy and safety of M605110 in patients with acne vulgaris

JRCT ID: jRCT2031220333

Registered date:13/09/2022

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: Acne vulgaris
• Date of first enrollment: 30/09/2022
• Target sample size: 240
• Study type: Interventional
• Intervention(s): Apply an appropriate amount of M605110 once a day.

Outcome(s)

• Primary Outcome: Percentage change in total lesion count

Key inclusion & exclusion criteria

• Age minimum: >= 9age old
• Age maximum: <= 49age old
• Gender: Both
• Include criteria: Patients with Acne vulgaris 9 to 49 years old

Exclude criteria

(1)Patients with concurrent presense of serious cardiac, hepatic, renal, plumonary, hematologic, or other diseases considered inappropriate for paticipation in the clinical study
(2)Patients with a history of hypersensitivity to investigational drug ingredients
(3)Pregnant or lactating women

Related Information

• Primary Sponsor: Tomoyuki Nishiura